Trental (Pentoxifylline) Indication
Trental (pentoxifylline) is FDA-approved for the treatment of intermittent claudication due to peripheral artery disease (PAD), though it should be considered only as a second-line alternative to cilostazol, as its clinical effectiveness is marginal and not well established.
Primary Indication: Intermittent Claudication
Pentoxifylline is approved for use in patients with intermittent claudication secondary to chronic occlusive arterial disease of the limbs 1. The standard dosing is 400 mg orally three times daily 2.
Evidence Quality and Positioning
According to the most recent 2017 AHA/ACC guidelines, pentoxifylline receives a Class III: No Benefit recommendation for treatment of claudication 3. This represents a significant downgrade from earlier guidelines:
- 2013 ACC/AHA guidelines classified pentoxifylline as Class IIb (may be considered as second-line alternative to cilostazol) 2
- 2006 ACC/AHA guidelines also gave it Class IIb status but noted "marginal" clinical effectiveness 1
Clinical Efficacy Data
The evidence supporting pentoxifylline is weak:
- Meta-analyses show only marginal improvement in walking distance: 21-29 meters for pain-free walking and 43-48 meters for maximal walking distance 1
- In a head-to-head trial of 471 patients, there was no significant difference between pentoxifylline and placebo in pain-free or maximal walking distance, while cilostazol showed clear benefit 1
- Pentoxifylline does not increase ankle-brachial index (ABI) at rest or after exercise 1
Treatment Algorithm for Claudication
First-line therapy:
- Supervised exercise training (30-45 minutes, ≥3 times weekly for ≥12 weeks) 2
- Cilostazol 100 mg twice daily (Class I recommendation) - contraindicated in heart failure 2, 3
Second-line consideration (historical):
- Pentoxifylline 400 mg three times daily - only if cilostazol is contraindicated or not tolerated 2
- Current 2017 guidelines recommend against its use 3
Other Potential Uses (Not FDA-Approved for These Indications)
Venous Leg Ulcers
Pentoxifylline shows efficacy as an adjunct to compression therapy for venous leg ulcers (RR 1.56,95% CI 1.14-2.13) and may work even without compression (RR 2.25,95% CI 1.49-3.39) 4.
Alcoholic Hepatitis
Pentoxifylline is no longer recommended for treatment of alcoholic hepatitis 5, 6. While previously considered for patients with contraindications to corticosteroids, recent evidence shows no survival benefit at 1,3, or 12 months 7.
Safety Profile
Common adverse effects (occurring in <3% of patients):
- Gastrointestinal disturbances (72% of all adverse effects): dyspepsia, nausea, diarrhea, sore throat 1, 4
- Overall adverse effect rate is higher than placebo (RR 1.56,95% CI 1.10-2.22) 4
- No life-threatening side effects reported, though trials have been too small to assess this reliably 1
Critical Clinical Caveat
Given the 2017 AHA/ACC guidelines' Class III: No Benefit recommendation 3, pentoxifylline should generally not be prescribed for intermittent claudication. If a patient cannot take cilostazol due to heart failure and has failed supervised exercise therapy, consider endovascular intervention rather than pentoxifylline, as the drug's marginal benefit does not justify its use in contemporary practice.